This document discusses elements of an effective deviation management program. It begins by defining deviation as any departure from standard operating procedures or quality requirements. An effective deviation management program includes risk management, root cause analysis, corrective and preventive action procedures, and data collection to assess effectiveness. Root cause analysis identifies underlying systemic causes of problems rather than just direct causes. Establishing the right corrective and preventive actions is important to eliminate or mitigate future risks of deviations. Managing deviations effectively supports quality, continuous improvement, and achieving organizational objectives.
This document discusses deviation handling and root cause analysis. It defines deviations as departures from standard procedures and outlines regulatory expectations to investigate deviations and prevent reoccurrence. The basic process flow for handling deviations includes identification, assessment, classification, investigation and corrective actions. Root cause analysis is presented as a method to systematically identify underlying causes of problems using techniques like brainstorming, 5 whys, and cause-and-effect diagrams. The goals of root cause analysis are failure identification, analysis, and resolution through an iterative process.
Lean what 21 CFR Parts 210 and 211 are and how you an implement these regulations in your organization. For more information and tips on compliance go to http://compliance-insight.com/fda-gcp-and-gmp-training/21-cfr-210-211/
This document discusses deviations and out-of-specification/out-of-trend results in the pharmaceutical industry. It defines deviations as unwanted events that differ from approved processes or standards. Deviations are classified as major, critical, or minor depending on their impact. Out-of-specification results occur when test results fall outside predetermined specifications, requiring investigation. Out-of-trend results differ from historical results but are still within specifications, also necessitating investigation. The document provides examples of planned and unplanned deviations as well as approaches to minimize out-of-specification results through good practices.
The document outlines the key aspects of current good manufacturing practices (cGMPs) that pharmaceutical manufacturers must follow. cGMPs come from the Food, Drug and Cosmetic Act and are enforced by the FDA. They help ensure safety and quality by requiring strict control over facilities, equipment, components, packaging, labeling, and processes. Key parts of cGMP regulations address organization, buildings, equipment, materials control, production, packaging, holding, distribution, and records. Failure to comply can result in serious legal and business consequences like product recalls or plant shutdowns.
Change control is a formal system by which qualified representatives of appropriate disciplines review proposed or actual changes that might effect a validated status. The intent is to determine the need for the action that would ensure that the system is maintained in a validated state.
Presentation complied by Drug Regulations – a not for profit organization from publicly available material form FDA , EMA, EDQM . WHO and similar organizations.
Visit www.drugregulations.org for the latest in Pharmaceutic
1) A systematic change control process is important in the pharmaceutical industry to ensure that any changes made to products or systems are properly documented, reviewed, and approved. Major changes may require regulatory approval while minor changes do not.
2) The procedure involves an initiating department submitting a change request form detailing the proposed change and its justification. Changes are classified as major or minor. Major changes such as formulation or manufacturing process changes require approval from quality assurance.
3) A structured change control system provides benefits like consistent management of changes, maintaining documentation and history of changes, and demonstrating regulatory compliance.
This document discusses deviation handling and root cause analysis. It defines deviations as departures from standard procedures and outlines regulatory expectations to investigate deviations and prevent reoccurrence. The basic process flow for handling deviations includes identification, assessment, classification, investigation and corrective actions. Root cause analysis is presented as a method to systematically identify underlying causes of problems using techniques like brainstorming, 5 whys, and cause-and-effect diagrams. The goals of root cause analysis are failure identification, analysis, and resolution through an iterative process.
Lean what 21 CFR Parts 210 and 211 are and how you an implement these regulations in your organization. For more information and tips on compliance go to http://compliance-insight.com/fda-gcp-and-gmp-training/21-cfr-210-211/
This document discusses deviations and out-of-specification/out-of-trend results in the pharmaceutical industry. It defines deviations as unwanted events that differ from approved processes or standards. Deviations are classified as major, critical, or minor depending on their impact. Out-of-specification results occur when test results fall outside predetermined specifications, requiring investigation. Out-of-trend results differ from historical results but are still within specifications, also necessitating investigation. The document provides examples of planned and unplanned deviations as well as approaches to minimize out-of-specification results through good practices.
The document outlines the key aspects of current good manufacturing practices (cGMPs) that pharmaceutical manufacturers must follow. cGMPs come from the Food, Drug and Cosmetic Act and are enforced by the FDA. They help ensure safety and quality by requiring strict control over facilities, equipment, components, packaging, labeling, and processes. Key parts of cGMP regulations address organization, buildings, equipment, materials control, production, packaging, holding, distribution, and records. Failure to comply can result in serious legal and business consequences like product recalls or plant shutdowns.
Change control is a formal system by which qualified representatives of appropriate disciplines review proposed or actual changes that might effect a validated status. The intent is to determine the need for the action that would ensure that the system is maintained in a validated state.
Presentation complied by Drug Regulations – a not for profit organization from publicly available material form FDA , EMA, EDQM . WHO and similar organizations.
Visit www.drugregulations.org for the latest in Pharmaceutic
1) A systematic change control process is important in the pharmaceutical industry to ensure that any changes made to products or systems are properly documented, reviewed, and approved. Major changes may require regulatory approval while minor changes do not.
2) The procedure involves an initiating department submitting a change request form detailing the proposed change and its justification. Changes are classified as major or minor. Major changes such as formulation or manufacturing process changes require approval from quality assurance.
3) A structured change control system provides benefits like consistent management of changes, maintaining documentation and history of changes, and demonstrating regulatory compliance.
Product development and technology transfer M pharmPoojaWadgave
1. The document discusses technology transfer in the pharmaceutical industry, which refers to transferring details about formulations and analytical methods from research and development to production. This includes transferring a drug product from laboratory scale to production scale.
2. It outlines the goals, objectives, methods, and importance of technology transfer. The key methods are licensing and technology transfer involves a framework including a feasibility study, scale-up, validation, and production batches.
3. Successful technology transfer requires establishing a technology transfer team representing different areas like quality assurance, production, and engineering to review documentation, manufacturing processes, and equipment needs.
Quality & compliance excellence in pharmaceuticalsAnvita Bharati
Quality can be defined in several ways including conformance to specifications, fitness for use, and value for price paid. It is judged based on factors like performance, reliability, and support services provided. Pharmaceutical products have higher quality standards and more regulations compared to consumer goods due to their intended use and potential risks. Ensuring compliance with various quality guidelines is important for patient safety and involves establishing quality systems, policies, procedures, documentation, and ongoing assessments like audits and corrective actions. Non-compliance can result in issues like complaints, recalls, and regulatory actions.
What is likely to go into the revised Annex 1, including:
Terminal sterilisation vs aseptic processing
WFI produced by reverse osmosis
Guidance for media simulation trials
This remains speculative
The document discusses quality management systems and the six system inspection model used by the FDA to ensure compliance with cGMP regulations. It describes each of the six systems - quality system, production system, facilities and equipment system, laboratory control system, materials system, and packaging and labeling system. For each system, it provides an overview and lists the relevant cGMP subparts that govern inspections of that system. The goal is to help pharmaceutical manufacturers implement quality systems to meet FDA requirements.
This document discusses quality auditing. It defines auditing and quality auditing, outlines quality auditing standards and types of audits. It describes audit activities like planning, information gathering, communication, drafting the audit report, and getting management response. The document explains roles of client, auditor and auditee in audits and the audit process from notification to feedback. It provides guidance on managing an audit program according to ISO 19011.
The document discusses ICH Q7, a guideline for good manufacturing practices for active pharmaceutical ingredients. It aims to improve quality, enhance productivity and effectiveness of API manufacturing. ICH Q7 applies to APIs made through chemical synthesis, extraction, fermentation or combinations and establishes requirements for quality management, personnel, facilities, equipment, documentation, materials management, production controls, packaging and more. Adherence to ICH Q7 helps ensure APIs are safe, effective and of good quality and prepared according to cGMP standards expected by regulatory agencies like the FDA.
In this slide contains definition, importance, benefits of annual product review.
Presented by: Ravi Sanker babu .D.V (Department of pharmaceutical analysis and quality assurance).
RIPER, anantapur.
The document discusses change control management according to cGMP guidelines. It defines change control and why it is important to have a formal change control system to evaluate any changes that could affect product quality. It provides details on how to classify, document, review and approve changes, as well as testing and validation requirements. Specific guidance is given for process, equipment, raw material and analytical method changes.
This document discusses change control in the pharmaceutical industry. It defines change and change control, and outlines the tasks, principles, regulatory requirements, and elements of a change control system. The document describes the steps in a typical change control process, including classifying, assessing, planning, implementing, evaluating, and closing changes. It provides examples of major and minor changes and discusses the documentation and challenges of maintaining an effective change control system. Maintaining proper communication, turnaround times, documentation, and training are important for managing changes in a controlled manner.
The document discusses batch production record (BPR) review and release. It defines key terms like deviations, critical process parameters, critical quality attributes. It outlines regulatory requirements from ICH Q7, CFR 211, and consequences of non-compliance. The objectives of BPR review are to confirm the batch quality and was produced under control. Records of critical steps must be reviewed and approved by quality before release. Failure to comply with cGMPs can render a drug adulterated under the FDA act.
Auditing of vendors and production departmentPRANJAY PATIL
The document discusses vendor audits in the pharmaceutical industry. It provides details on the objectives, parameters, and steps of conducting a vendor audit. The key points are:
- Vendor audits assess a vendor's quality management system, practices, documentation, and adherence to standards to ensure their products and services meet requirements.
- Important parameters reviewed include ISO certifications, manufacturing facilities, packaging and labeling standards, and data handling procedures.
- The goals are to evaluate quality control measures and management commitment to quality standards required by regulations.
- Conducting vendor audits helps reduce costs and risks by gaining insight into supplier processes and compliance.
This document outlines a procedure for change control at an organization. It defines change control as a quality tool to maintain records of all changes as a history. Changes can relate to facilities, documentation, systems, equipment, instruments, procedures, layouts, and products. Changes are categorized as minor, major, or critical based on their impact. The change control process involves initiating a change, getting approvals from relevant departments, implementing the change, reviewing and closing out the change control. A numbering system is used to track changes and all records are maintained by the quality assurance department.
A structured approach to the investigation process should be used with the objective of determining the root cause.
The level of effort, formality, and documentation of the investigation should be commensurate with the level of risk, in line with ICH Q9.
Validation of Heat ventilation air conditioningPrashant Tomar
This document discusses the user requirement specifications (URS), design qualification (DQ), installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ) of heating, ventilation, and air conditioning (HVAC) systems used in pharmaceutical plants. The HVAC system must be qualified to ensure it is designed and installed properly and works as expected. The URS define the room temperature, humidity, and air cleanliness requirements. The DQ confirms the design meets the URS. The IQ verifies correct installation. The OQ tests the system operation. Finally, the PQ assesses the HVAC performance under normal operating conditions.
This document discusses supplemental new drug applications (SNDA) which are submitted to the FDA for approval of changes to approved drugs. It defines what types of changes require an SNDA, including manufacturing changes, formulation changes, and labeling changes. It categorizes changes as major, moderate, or minor based on their potential impact on quality, safety, or efficacy. Major changes require prior approval, moderate changes require 30 days' notice, and minor changes are reported annually. Examples are provided for each category of change.
This document discusses concepts of change control, out of specifications (OOS), and out of trends (OOT) in pharmaceutical quality assurance. It defines change control as a procedure to review, verify, regulate, manage, approve and control changes made to systems or processes. OOS refers to test results that fall outside pre-defined acceptance criteria, while OOT describes results that do not follow expected trends. The document outlines procedures for investigating and managing changes, OOS, and OOT to ensure product quality and compliance with regulations.
This document discusses out-of-trend (OOT) results, which occur when a result does not follow the expected trend based on past data. It notes that identifying OOT results is becoming a regulatory issue and introduces some statistical approaches for doing so, like using a minimum of 25 batches to set a trend range of average ±3 standard deviations. Some challenges of implementing OOT identification for commercial batches are determining the appropriate statistical approach, data requirements, and investigation process. The conclusion states that identifying OOT results is important for regulators and industry, and the method should not be too complex.
CHAPTER-1 Information Gathering and Administration.pdfDr. Dinesh Mehta
During the audit, information relevant to the objectives, scope and criteria, including information on interfaces between functions, activities and processes, should be collected by appropriate sampling and should be verified.
Insights and Trends from 2021 FDA GCP Inspections.pptxMMS Holdings
The document summarizes insights and trends from the FDA's 2021 GCP inspections. It provides an overview of total inspections, top 483 observations for drugs and devices, and warning letters. Key findings include COVID-19 reducing inspections and alternative tools being used, top drug and device 483 observations relating to documentation and procedures, and most warning letters issued in March and October relating to drugs. It also discusses anticipated changes from the draft ICH E6(R3) guideline and trends for 2022, such as a potential increase in enforcement and focus on data security, quality controls, and corrective actions.
Risk management is a systematic process of assessing, controlling, communicating, and reviewing risks associated with equipment, processes, materials, facilities, distribution, and patients. It involves identifying potential failure modes and their causes and effects, analyzing risks, and prioritizing critical risks. Tools like Failure Mode and Effects Analysis (FMEA) are commonly used to structure the risk analysis and management process. The goal is to design quality into processes and products throughout the product lifecycle to maintain quality and minimize risks.
Product development and technology transfer M pharmPoojaWadgave
1. The document discusses technology transfer in the pharmaceutical industry, which refers to transferring details about formulations and analytical methods from research and development to production. This includes transferring a drug product from laboratory scale to production scale.
2. It outlines the goals, objectives, methods, and importance of technology transfer. The key methods are licensing and technology transfer involves a framework including a feasibility study, scale-up, validation, and production batches.
3. Successful technology transfer requires establishing a technology transfer team representing different areas like quality assurance, production, and engineering to review documentation, manufacturing processes, and equipment needs.
Quality & compliance excellence in pharmaceuticalsAnvita Bharati
Quality can be defined in several ways including conformance to specifications, fitness for use, and value for price paid. It is judged based on factors like performance, reliability, and support services provided. Pharmaceutical products have higher quality standards and more regulations compared to consumer goods due to their intended use and potential risks. Ensuring compliance with various quality guidelines is important for patient safety and involves establishing quality systems, policies, procedures, documentation, and ongoing assessments like audits and corrective actions. Non-compliance can result in issues like complaints, recalls, and regulatory actions.
What is likely to go into the revised Annex 1, including:
Terminal sterilisation vs aseptic processing
WFI produced by reverse osmosis
Guidance for media simulation trials
This remains speculative
The document discusses quality management systems and the six system inspection model used by the FDA to ensure compliance with cGMP regulations. It describes each of the six systems - quality system, production system, facilities and equipment system, laboratory control system, materials system, and packaging and labeling system. For each system, it provides an overview and lists the relevant cGMP subparts that govern inspections of that system. The goal is to help pharmaceutical manufacturers implement quality systems to meet FDA requirements.
This document discusses quality auditing. It defines auditing and quality auditing, outlines quality auditing standards and types of audits. It describes audit activities like planning, information gathering, communication, drafting the audit report, and getting management response. The document explains roles of client, auditor and auditee in audits and the audit process from notification to feedback. It provides guidance on managing an audit program according to ISO 19011.
The document discusses ICH Q7, a guideline for good manufacturing practices for active pharmaceutical ingredients. It aims to improve quality, enhance productivity and effectiveness of API manufacturing. ICH Q7 applies to APIs made through chemical synthesis, extraction, fermentation or combinations and establishes requirements for quality management, personnel, facilities, equipment, documentation, materials management, production controls, packaging and more. Adherence to ICH Q7 helps ensure APIs are safe, effective and of good quality and prepared according to cGMP standards expected by regulatory agencies like the FDA.
In this slide contains definition, importance, benefits of annual product review.
Presented by: Ravi Sanker babu .D.V (Department of pharmaceutical analysis and quality assurance).
RIPER, anantapur.
The document discusses change control management according to cGMP guidelines. It defines change control and why it is important to have a formal change control system to evaluate any changes that could affect product quality. It provides details on how to classify, document, review and approve changes, as well as testing and validation requirements. Specific guidance is given for process, equipment, raw material and analytical method changes.
This document discusses change control in the pharmaceutical industry. It defines change and change control, and outlines the tasks, principles, regulatory requirements, and elements of a change control system. The document describes the steps in a typical change control process, including classifying, assessing, planning, implementing, evaluating, and closing changes. It provides examples of major and minor changes and discusses the documentation and challenges of maintaining an effective change control system. Maintaining proper communication, turnaround times, documentation, and training are important for managing changes in a controlled manner.
The document discusses batch production record (BPR) review and release. It defines key terms like deviations, critical process parameters, critical quality attributes. It outlines regulatory requirements from ICH Q7, CFR 211, and consequences of non-compliance. The objectives of BPR review are to confirm the batch quality and was produced under control. Records of critical steps must be reviewed and approved by quality before release. Failure to comply with cGMPs can render a drug adulterated under the FDA act.
Auditing of vendors and production departmentPRANJAY PATIL
The document discusses vendor audits in the pharmaceutical industry. It provides details on the objectives, parameters, and steps of conducting a vendor audit. The key points are:
- Vendor audits assess a vendor's quality management system, practices, documentation, and adherence to standards to ensure their products and services meet requirements.
- Important parameters reviewed include ISO certifications, manufacturing facilities, packaging and labeling standards, and data handling procedures.
- The goals are to evaluate quality control measures and management commitment to quality standards required by regulations.
- Conducting vendor audits helps reduce costs and risks by gaining insight into supplier processes and compliance.
This document outlines a procedure for change control at an organization. It defines change control as a quality tool to maintain records of all changes as a history. Changes can relate to facilities, documentation, systems, equipment, instruments, procedures, layouts, and products. Changes are categorized as minor, major, or critical based on their impact. The change control process involves initiating a change, getting approvals from relevant departments, implementing the change, reviewing and closing out the change control. A numbering system is used to track changes and all records are maintained by the quality assurance department.
A structured approach to the investigation process should be used with the objective of determining the root cause.
The level of effort, formality, and documentation of the investigation should be commensurate with the level of risk, in line with ICH Q9.
Validation of Heat ventilation air conditioningPrashant Tomar
This document discusses the user requirement specifications (URS), design qualification (DQ), installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ) of heating, ventilation, and air conditioning (HVAC) systems used in pharmaceutical plants. The HVAC system must be qualified to ensure it is designed and installed properly and works as expected. The URS define the room temperature, humidity, and air cleanliness requirements. The DQ confirms the design meets the URS. The IQ verifies correct installation. The OQ tests the system operation. Finally, the PQ assesses the HVAC performance under normal operating conditions.
This document discusses supplemental new drug applications (SNDA) which are submitted to the FDA for approval of changes to approved drugs. It defines what types of changes require an SNDA, including manufacturing changes, formulation changes, and labeling changes. It categorizes changes as major, moderate, or minor based on their potential impact on quality, safety, or efficacy. Major changes require prior approval, moderate changes require 30 days' notice, and minor changes are reported annually. Examples are provided for each category of change.
This document discusses concepts of change control, out of specifications (OOS), and out of trends (OOT) in pharmaceutical quality assurance. It defines change control as a procedure to review, verify, regulate, manage, approve and control changes made to systems or processes. OOS refers to test results that fall outside pre-defined acceptance criteria, while OOT describes results that do not follow expected trends. The document outlines procedures for investigating and managing changes, OOS, and OOT to ensure product quality and compliance with regulations.
This document discusses out-of-trend (OOT) results, which occur when a result does not follow the expected trend based on past data. It notes that identifying OOT results is becoming a regulatory issue and introduces some statistical approaches for doing so, like using a minimum of 25 batches to set a trend range of average ±3 standard deviations. Some challenges of implementing OOT identification for commercial batches are determining the appropriate statistical approach, data requirements, and investigation process. The conclusion states that identifying OOT results is important for regulators and industry, and the method should not be too complex.
CHAPTER-1 Information Gathering and Administration.pdfDr. Dinesh Mehta
During the audit, information relevant to the objectives, scope and criteria, including information on interfaces between functions, activities and processes, should be collected by appropriate sampling and should be verified.
Insights and Trends from 2021 FDA GCP Inspections.pptxMMS Holdings
The document summarizes insights and trends from the FDA's 2021 GCP inspections. It provides an overview of total inspections, top 483 observations for drugs and devices, and warning letters. Key findings include COVID-19 reducing inspections and alternative tools being used, top drug and device 483 observations relating to documentation and procedures, and most warning letters issued in March and October relating to drugs. It also discusses anticipated changes from the draft ICH E6(R3) guideline and trends for 2022, such as a potential increase in enforcement and focus on data security, quality controls, and corrective actions.
Risk management is a systematic process of assessing, controlling, communicating, and reviewing risks associated with equipment, processes, materials, facilities, distribution, and patients. It involves identifying potential failure modes and their causes and effects, analyzing risks, and prioritizing critical risks. Tools like Failure Mode and Effects Analysis (FMEA) are commonly used to structure the risk analysis and management process. The goal is to design quality into processes and products throughout the product lifecycle to maintain quality and minimize risks.
This document provides an overview of a presentation on risk management. It outlines the objectives of the presentation which are to provide a practical approach and tools to implement enterprise risk management. It discusses basic risk management concepts such as risks being uncertainties that can affect objectives, and the need to consider both threats and opportunities. It also presents a simple risk management framework of establishing objectives, identifying risks and controls, assessing risks, evaluating actions, and monitoring. The presentation aims to help participants start implementing risk management in their own organizations.
This document provides an overview of a presentation on risk management. It outlines the objectives of the presentation which are to provide a practical approach and tools to implement enterprise risk management. It discusses basic risk management concepts such as risks being uncertainties that can affect objectives, and the need to consider both threats and opportunities. It also presents a simple risk management framework of establishing objectives, identifying risks and controls, assessing risks, evaluating and taking action, and monitoring. The presentation aims to help participants start implementing risk management in their own organizations.
This document provides an overview of a presentation on risk management. It outlines the objectives of the presentation which are to provide a practical approach and framework for risk management and tools to implement enterprise risk management. It discusses basic concepts such as defining risk, threats and opportunities, and enterprise vs integrated risk management. It also presents a simple risk management framework and examples of how to categorize, prioritize, and measure risks. Key points are made about establishing a risk management process and embedding it into organizational processes.
The document defines risk and issue, outlines the risk lifecycle and management cycle, and provides details on risk identification, analysis, assessment, and management. Key points include:
- A risk is a potential future event that could negatively impact objectives, while an issue is a current problem.
- The risk management cycle includes identifying risks, assessing them, selecting strategies, implementing controls, and monitoring/evaluating.
- Risk identification involves knowing the organization's assets and sources of risk. Risk analysis assesses the likelihood and impact of risks.
This document discusses hazard analysis and risk assessment. It defines hazard and risk, and outlines the main steps in hazard analysis and risk assessment. These include identifying hazards, determining who may be harmed and how, assessing dose-response and exposure, risk management and control. Hazard analysis techniques include checklists, safety audits, preliminary hazard analysis, failure modes and effects analysis, what-if analysis, and hazard and operability studies. Risk assessment involves quantifying risk based on probability and severity. The document emphasizes that hazard analysis and risk assessment should be ongoing processes throughout the lifecycle of a system.
The document discusses ISO 9001:2015 and the importance of understanding context, risk-based thinking, and decision making. It provides the following key points:
1) Understanding context involves determining internal and external issues relevant to the organization's purpose and strategic direction that can impact the quality management system. The internal and external context includes factors like vision, resources, customer needs, regulations, and market trends.
2) Risk-based thinking involves identifying risks and opportunities associated with the organization's objectives and context. This includes assessing risks throughout processes like purchasing, design and development, and taking actions to address risks.
3) Decision making in ISO 9001:2015 should be based on evidence and address risks and opportunities related
The document discusses ISO 9001:2015 and the importance of understanding context, risk-based thinking, and decision making. It provides the following key points:
1) Understanding context involves determining internal and external issues relevant to the organization's purpose and strategic direction that affect its quality management system. The internal context includes aspects like vision, culture, and resources while the external context covers legal, social, political, and economic factors.
2) Risk-based thinking involves identifying risks and opportunities in key processes like purchasing, design and development, and addressing uncertainties proactively. Process owners should define processes, metrics, risks, and review performance.
3) Decisions should be based on evidence found by understanding context,
The document discusses ISO 9001:2015 and the importance of understanding context, risk, and opportunities. It provides the following key points:
1) Organizations must determine internal and external issues relevant to their purpose and strategic direction that affect their quality management system. Understanding context is key to decision making.
2) Risk-based thinking involves proactively identifying and managing uncertainties. Organizations should analyze risks and opportunities within their processes and address high priority issues.
3) Process definition, review, and management should include identifying inputs, outputs, metrics, owners, and risks to ensure proper management and improvement.
Risk management in pharmaceutical IndustryMahesh shinde
This document provides an overview of risk management in the pharmaceutical industry. It discusses the objectives, scope, definitions, and tools used in risk management. The key tools covered include Failure Mode and Effects Analysis (FMEA), Fault Tree Analysis (FTA), Hazard Analysis and Critical Control Points (HACCP), and Preliminary Hazard Analysis (PHA). The goal of risk management is to identify potential risks, evaluate their likelihood and impact, and develop control measures to mitigate risks and ensure product quality and safety.
This document discusses quality risk management (QRM) and provides an overview of key QRM principles and processes. It defines key risk management terms and describes common risk management tools. The document outlines the general QRM process, which includes risk assessment, control, communication and review. It emphasizes that the level of effort for QRM should be commensurate with the level of risk. Various risk management tools are also described, including failure mode and effects analysis, hazard analysis, hazard operability analysis, and fishbone diagrams.
This presentation covered hazard identification and risk management. The key objectives were to develop procedures for ongoing hazard identification and risk assessment, include hazard identification when planning workplace changes, develop and follow procedures for selecting and implementing risk controls according to the hierarchy of control and WHS requirements, identify inadequacies in existing risk controls and provide resources for improvement, and identify when expert WHS advice is required.
Expounds on the Principles, Steps and Execution of a proper Quality Risk Management process as eluded in the ICH QRM guidelines - Q9 as well as WHO Guidelines
1) The document discusses enterprise risk management concepts and frameworks. It outlines key risks faced in healthcare such as regulatory risks, operational risks, and reputational risks.
2) An effective risk management program can help organizations avoid surprises, improve governance, and ensure objectives are met without disruptions. The document provides examples of risk organization structures and processes for identification, assessment, and response.
3) Moving forward, the organization will validate risk registers, identify top 15 risks for rigorous management, and review mitigation progress of these risks in monthly leadership meetings. A risk polarization survey will also be conducted regularly.
The document discusses various tools and methods for hazard and risk management. It describes 12 different tools/methods: self-protective measures, training and reinforcement, communication/incentives, risk definition, risk assessment, risk control hierarchy, proactive vs reactive approaches, CAPA process, product review requirements, hazard identification/assessment/control process, and statistical tools like control charts. For each, it provides an overview and potential applications in risk management.
This document provides an overview of corporate risk management. It defines risk according to ISO 31000:2009 as "the effect of uncertainty on objectives." It notes that managing risk can both reduce negative impacts and increase positive impacts for business. The document outlines key elements of risk management including risk causes, factors, and failures. It discusses the evolution of risk management from compliance-focused to business optimization-focused. It provides examples of establishing the context, risk assessment, treatment, and monitoring within a risk management process. Finally, it gives criteria for measuring likelihood, impact, risk rating, risk treatment effectiveness, and different risk treatment measures.
Understanding the principles and practicalities of risk assessment
Understanding risk evaluation
Selecting and implementing control measures
Monitoring and reviewing
EC Directive 89/391/EEC
IEC/ISO 31010:2009
8 strategic planning linking analysis with results anti-corruption anga re...PACDE
RBM helps connect activities to goals and determine if goals are achieved. It focuses on results instead of activities and improves transparency, accountability, and performance measurement. While challenging to apply due to issues attributing outcomes to specific interventions, RBM can be effective for anti-corruption work if the right country-level indicators are selected and qualitative data supports quantitative findings. UNDAFs should include anti-corruption outputs and outcomes when relevant and use a mix of global perception indices and national surveys to track anti-corruption results over time.
How to Make a Field Mandatory in Odoo 17Celine George
In Odoo, making a field required can be done through both Python code and XML views. When you set the required attribute to True in Python code, it makes the field required across all views where it's used. Conversely, when you set the required attribute in XML views, it makes the field required only in the context of that particular view.
This presentation was provided by Racquel Jemison, Ph.D., Christina MacLaughlin, Ph.D., and Paulomi Majumder. Ph.D., all of the American Chemical Society, for the second session of NISO's 2024 Training Series "DEIA in the Scholarly Landscape." Session Two: 'Expanding Pathways to Publishing Careers,' was held June 13, 2024.
Philippine Edukasyong Pantahanan at Pangkabuhayan (EPP) CurriculumMJDuyan
(𝐓𝐋𝐄 𝟏𝟎𝟎) (𝐋𝐞𝐬𝐬𝐨𝐧 𝟏)-𝐏𝐫𝐞𝐥𝐢𝐦𝐬
𝐃𝐢𝐬𝐜𝐮𝐬𝐬 𝐭𝐡𝐞 𝐄𝐏𝐏 𝐂𝐮𝐫𝐫𝐢𝐜𝐮𝐥𝐮𝐦 𝐢𝐧 𝐭𝐡𝐞 𝐏𝐡𝐢𝐥𝐢𝐩𝐩𝐢𝐧𝐞𝐬:
- Understand the goals and objectives of the Edukasyong Pantahanan at Pangkabuhayan (EPP) curriculum, recognizing its importance in fostering practical life skills and values among students. Students will also be able to identify the key components and subjects covered, such as agriculture, home economics, industrial arts, and information and communication technology.
𝐄𝐱𝐩𝐥𝐚𝐢𝐧 𝐭𝐡𝐞 𝐍𝐚𝐭𝐮𝐫𝐞 𝐚𝐧𝐝 𝐒𝐜𝐨𝐩𝐞 𝐨𝐟 𝐚𝐧 𝐄𝐧𝐭𝐫𝐞𝐩𝐫𝐞𝐧𝐞𝐮𝐫:
-Define entrepreneurship, distinguishing it from general business activities by emphasizing its focus on innovation, risk-taking, and value creation. Students will describe the characteristics and traits of successful entrepreneurs, including their roles and responsibilities, and discuss the broader economic and social impacts of entrepreneurial activities on both local and global scales.
How to Setup Warehouse & Location in Odoo 17 InventoryCeline George
In this slide, we'll explore how to set up warehouses and locations in Odoo 17 Inventory. This will help us manage our stock effectively, track inventory levels, and streamline warehouse operations.
Level 3 NCEA - NZ: A Nation In the Making 1872 - 1900 SML.pptHenry Hollis
The History of NZ 1870-1900.
Making of a Nation.
From the NZ Wars to Liberals,
Richard Seddon, George Grey,
Social Laboratory, New Zealand,
Confiscations, Kotahitanga, Kingitanga, Parliament, Suffrage, Repudiation, Economic Change, Agriculture, Gold Mining, Timber, Flax, Sheep, Dairying,
This presentation was provided by Rebecca Benner, Ph.D., of the American Society of Anesthesiologists, for the second session of NISO's 2024 Training Series "DEIA in the Scholarly Landscape." Session Two: 'Expanding Pathways to Publishing Careers,' was held June 13, 2024.
A Visual Guide to 1 Samuel | A Tale of Two HeartsSteve Thomason
These slides walk through the story of 1 Samuel. Samuel is the last judge of Israel. The people reject God and want a king. Saul is anointed as the first king, but he is not a good king. David, the shepherd boy is anointed and Saul is envious of him. David shows honor while Saul continues to self destruct.
2. What is
Deviation?o It is a departure or divergence from an anticipated
result or outcome
o WHO characterizes deviation as any departure from
an established SOP, a validated process or other
quality related requirement
o Other terms for deviation:
o Nonconformity
o Incident/Accident
o Event
o Error or Mistake
3. Deviation Management
o It is the process of dealing with and controlling
deviation
o Deviation Management is an essential element in any
well-established Quality Management System
o Deviation Management plays a key role in:
o Ensuring the quality of service
o The continuous improvement of work processes
o There is a direct relation between deviation
management and continuous improvement
5. o We have all the policies, processes and procedures in
place; therefore there are going to be no mistake!
o We invest so much in the training of our employees so
as to achieve perfect performance
o Most mistakes are due to human error
• To prevent errors from happening you need to:
• Look at systems and processes
• Go upstream (high level) in the process and
make sure that any risk of a deviation is
eliminated before it goes downstream to
produce an event or error
o We will check mistakes out of the system
o Introduce another level of checks and balances to
ensure that no mistakes happen
o If a mistake happens we will council our employees
and retrain them
6. What is an effective
Deviation
Management Program?
o A deviation management program should include a
mechanism to differentiate deviations or
nonconformities based on their relevance or risk
o A deviation management program has to distinguish
between nonconformities that will affect the quality of
service and those that will have little impact on the
established norms
o Risk management has always been a part of an
analysis process linked to the handling of deviations or
nonconformities
7. What is an effective
Deviation Management
Program? (Cont’d)
o A deviation management program should include a root cause
analysis component that will determine the systemic cause of an
event or nonconformity
o Root cause analysis helps focus resources on performing a good
quality investigation to determine the actual cause of an
nonconformity
o Root cause analysis enables problem solvers to distinguish the
“vital few” from the “trivial many” causes of a problem
8. What is an effective
Deviation Management
Program? (Cont’d)
o An effective deviation management program
should include a mechanism to determine the
corrective/preventive actions (CAPA) to be taken
in order to eliminate causes or potential causes
of nonconformities
o A corrective/preventive action procedure
implements corrective or preventive measures
that are appropriate to the significance of the risk
or potential risk for a deviation event
o A deviation handling program should include a
mechanism to collect data and evaluate the
effectiveness of the corrective/preventive action
taken
9. Elements of an Effective
Deviation Management
Program
o Risk Management
o Root Cause Analysis
o Corrective/Preventive Action Procedure
o Data Collective to assess effectiveness
11. What is Risk?
o Uncertain event
o Always in the
future
o Has a cause and
effect (Impact)
o Has the potential
to impact
(negatively)
objectives or
outcomes
12. Risks: Known and Unknown
o Known Risks:
o Are predictable to a degree
o Can be identified, analyzed and
proactively managed
o Unknown Risk:
o A potential hazard that is completely
unknown
o In the context of risk management it is
any risk that is not identified and
managed
13. Hazard vs Risk
o In order to quantify risk there should precede a
measure of identifying and creating a hazard
inventory
o Risk frequency and severity is a function of the
measure of hazards identified in a process and
/or procedure
o Risk and hazard has to be considered in two
consecutive phases
o Risk Assessment: is the phase of
identification and categorization of hazards
o Risk Control: is the phase of risk reduction or
(acceptance)
15. Risk
o Risk can be mathematically expressed
in terms of two parameters:
o Severity (S)
o Frequency (F)
o Risk = SxF
o Risk evaluation is an answer to the
double question
o What probability?
o Which consequences?
16. What is an Acceptable
Risk?o The risk is sufficiently low in frequency and minimal in its impact
that it is not considered cost effective to control
o There is not yet a treatment or control of such risk
o The benefits outweigh any perceived risk
17. Quality Risk Management
(QRM)
o QRM is a process for the identification, assessment and
prioritization* of risk followed by;
o A coordinated and economic deployment of resources to
minimize or eliminate, if possible, the probability and/or
negative impact of a deviation or nonconformity
o QRM has become a mandatory requirement in the
manufacturing and service sector including healthcare
20. Prerequisites
o In order to implement a risk management program
effectively it is vital that a risk management
culture be developed
o Risk management culture would support the
vision, mission and objectives of an organization
o Limits and boundaries should be established and
communicated concerning what are acceptable
risk practices and outcomes
21.
22. Establish the Context
o QRM enables an organization:
• To understand the environment in which the
organization operates
• The external environment
• The internal culture
o To undertake a number of environmental analyses:
• Review of regulatory requirements
• Review of codes and standards
• Review of industry guidelines
23. Identify Risk
o When, where, how and why are
risks are likely to occur when
you implement a certain process
or procedure
o What risks are there when we
achieve our priorities
o What risks are there when we
forgo our priorities
24. Risk Analysis
o Consideration of the sources of risk
• Identification of the sources of risk is the most critical stage
of risk assessment
• The better understanding of the sources of risk the better
outcome of risk assessment process and the more
meaningful and effective the management of risk will be
o The likelihood (frequency) and impact (severity) of risks
o Identification and evaluation of controls
• Estimation of their effectiveness
• Level of risk (residual risk) after controls are put in place
25.
26. o Promotes the safety, security and well being of staff
members, patients and the community at large
o Enables a better understanding of work processes and
procedures
o Provides an opportunity for continuous improvement of
work processes and procedures
28. What is Root Cause
Analysis?
o Is a problem solving approach for identifying
underlying causes of problems so that the
most effective solutions can be determined
and implemented
o Goes beyond the obvious (proximate,
immediate, direct) cause of a problem and
investigates deeper underlying causes
o Requires logical thinking about cause-effect
relationships
o Is a paradigm shift in the way problems are
identified and resolved
29. Machine is
producing defective
parts
A device on the
machine is
damaged
Hit by a forklift
The yellow
lines that
guide the
driver of the
forklift around
the machine
have worn off
There is no
policy/process
for reviewing
the status of
these lines and
repainting
them when
needed
Why?
Why?
Why?
Why?
Problem
Root Cause
30. Think System and
Process
Toast is burned
Toaster did
not eject
bread on time
Bread crumps
build-up
interfered
with
mechanism
No
policy/process
for cleaning
toaster regularly
Direct
Cause
System or
Root Cause
Symptom
or Problem
31. Root Cause
Analysis
o It is a skill that can be applied to nearly any
problem
People become proficient over time and
from repeated experience
o Only systemic causes are considered root
causes
• It is the policy, process, or procedure that
needs to be changed or modified to
prevent future recurrence
32. When to Use Root
Cause Analysis?
o There is high frequency of failure
o There is a significant negative impact on
established objective and outcomes
o There is a significant negative impact on
others
o There is high cost associated with such
failure
33. Root Cause Analysis
Steps
o Define the problem
o Understand the process
o Identify possible causes
o Collect data
o Analyze the data
o Identify and select the best solution
o Implement, evaluate and
institutionalize
34. Define the Problem
o A problem well stated is a problem half
solved
o A good problem definition can help make
the diagnosis more focused
o Components of a good problem statement
include the following:
What: description of what happened
Where: description of where the
problem was found
Who: if the problem affects individuals
or groups
When: the problem was first identified
How much: frequency and/or
magnitude
37. Auto Mechanic Shop
Problem
o How much did it increase (>tolerance
limits)?
o What was the average before and what
is it now?
o Was is it sudden or gradual increase
(trending)?
o Is there a specific kind of work done on
those cars that were not ready for pick
up?
38. Combination of Causes:
Convenience Store Example
o Takes too long to fill gas
o Goods bought from the store
damaged
o Store not clean
o Prices too high
o Too much trash around
o Should management take all these
complaints together and starts working
on them?
o Should management focus on those
complaints that have the highest impact?
39. Pareto Principle (80/20
Law)
o Named after the Italian economist Vilfredo Pareto
o Principle was based on an observation
that Pareto made in his garden
o He observed that 80% of his peas are
produced by 20% of the peapods
o Pareto principle is now used in
different disciplines:
Economics
Management
Business
Sports
Occupational Health & Safety
o Pareto used this information to show
that 80% of wealth in Italy at his time
was owned by 20% of the population
40. Complaints # of complaints
Non food items
damaged 102
Prices too high 65
Take too long to fill gas 162
Food items damaged 84
Too much trash around 31
Refrigerator looks dirty 16
Other 47
Complaints # of complaints
Take too long to fill
gas 162
Non food items
damaged 102
Food items
damaged 84
Prices too high 65
Other 47
Too much trash
around 31
Refrigerator looks
dirty 16
Complaints
# of
complaints
Cumulativ
e
%
cumulative
Too long to fill gas 162 162 32%
Non food items
damaged 102 264 52%
Food items damaged 84 348 69%
Prices too high 65 413 81%
Other 47 460 91%
Too much trash
around 31 491 97%
Fridge looks dirty 16 507 100%
Pareto Analysis
Convenience store
example
43. Understand the Process
o It is all about stepping back and taking a broad view of the
problem before jumping to possible causes
o This is achieved by mapping out the process by constructing
a flowchart
Define
Policy
Communic
ate policy
Impleme
nt policy
Monitor
complian
ce
Provide
feedbac
k
44.
45. Cytotech places
order in System
Test labels are
generated
Tech assistant
dates a blank
sheet and affixes
one label on it
Tech assistant
affixes the other
label on sample
vial
Disoposes of
remaining vials
once all cases are
verified
Cytotech places the
labels in the prep
area
Tech assistant
makes a copy of
sheet and keeps
original on file
Tech assistant
submits vials and
sheet to micro at the
end of each day
Ordering HPV DNA Testing
The Problem:
One day a physician called
complaining that there is no
HPV result for her patient
even though final report
indicated that an HPV DNA
test has been ordered.
Note: One month passed
before this physician
contacted our lab
46. Cytotech places
order in System
Test labels are
generated
Cytotech dates a
blank sheet and
affixes one label
on it
Cytotech affixes
the other label on
sample vial
Disoposes of
remaining vials
once the cases are
verified
Cytotech places the
labels in the prep
area
Tech assistant makes a
copy of sheet and
keeps the original on
file
Tech assistant
submits vials and
sheet to micro at the
end of each day
Ordering HPV DNA Testing
Cytotech collects
vials and places them
in a designated
location along with
the sheet for the tech
assistant to pick up
Before disposing of
vials tech assistant
checks age on vial
and makes a list of
all samples with ages
30-65
Tech assistant
submits the list to
cytotech to
investigate
48. Corrective & Preventive
Action
o Correction:
o Corrective
Action:
o Preventive
Action:
Is an action taken to address a
particular instance of
noncompliance (deviation)
Is an action take to prevent the
recurrence in the future of a
noncompliance that has been
found
• Is an action taken to prevent a
noncompliance in the firs place
• If the preventive action had been in
place the problem would not have
occurred
49. The Problem
o Customers who bought the newly
released model complained that the
seat belt is not fastening properly
o The company should launch an
investigation to collect as much
information as possible so as to state
the problem properly and clearly
• What?
• Where?
• When?
• How often?
• How serious?
50. Immediate/Direct Cause
o Investigation has shown that the
seatbelt clip was faulty and it was not
aligning properly
Problem Containment
(Correction)o Company contacts all customers who
complained and replaces the defective
seatbelt
o Company recalls all released model
and replaces sea belt
Prevent this deviation from recurring
(Corrective Action)
o Root Cause Analysis to determine the
systemic or process cause of the problem
o Investigate other hazards in the process
(risk management) that could cause such a
problem in the future and to mitigate their
effect or even eliminate them
Preventive Action
52. Final Word
“It is not enough to do your
best; you must know what
to do and then do your
best”
Edward
Deming
(Quality Guru)
Editor's Notes
Give an example of a laboratory that has set a patient turnover
Prioritization: not all risk are created equal. E.g. storage where non-temperature sensitive material vs temperature sensitive material
Vision: is what an organization aspires to be (aspirational)
Mission: is what an organization really does
Key questions
You are basically establishing a profile for each risk or category of risks
Paradigm: is a model
Trending: to develop a general direction
Trending helps problem solvers see the problem more clearly.
% of customers whose vehicles were not ready for pick up when promised has increased in the past three months
Tolerance limit is the outer limit of an anticipated outcome
Convenience Store problem: customer complaints
Option1: dispersing resources and energy
Sometimes you need to do what is called “Problem Containment”.
Vilfredo Pareto was a multitalented person: engineer, sociologist, economist, political scientist and philosopher. Died in 1923.
Pareto principle is also called the law of “vital few”.
In sports: 20% of exercises and habits has the most impact on athletes
In OSH: 20% of hazard cause more than 80% of injuries
Example of a basic flowchart (serial flowchart) and very easy to construct. Let’s say a company wants to diagnose a policy compliance issue
Oval: beginning.
Diamond: Decision
Rectangle: process component
Circle: Connector